Study results showed significant improvements in Erythema, Infiltration, Excoriation and Lichenification scores. In addition, subjects responding to a post treatment evaluation questionnaire indicated a substantial benefit when rating effectiveness, itching and appearance. This study indicates that Relieva® is useful in adult patients with atopic dermatitis.
Oldsmar, FL (PRWEB) November 28, 2007 — The results of the study conducted in the USA. to determine the efficacy and tolerability of Relieva® in adult patients with Atopic Dermatitis (eczema) were just published in the September issue of the American Journal of Therapeutics (14:442-446, 2007).
Previous laboratory studies showed that Psorberine®, the active ingredient of Relieva®, a non-corticoid, non- immunosuppressant but potent anti-inflammatory compound might be effective in atopic dermatitis. A clinical trial was conducted to determine if indeed Relieva® is efficacious in these patients.
Patients enrolled in this 12 week trial carried out by Global Clinicals Inc. were treated with Relieva®, a topical preparation containing Psorberine in Novasome®, a proprietary liposome formulation. Efficacy and safety was assessed using EASI (Eczema Area and Severity Index), an established index used for evaluating the severity of the signs of atopic dermatitis and a Subject Reported Evaluation of Treatment.
Study results showed significant improvements in Erythema, Infiltration, Excoriation and Lichenification scores. In addition, subjects responding to a post treatment evaluation questionnaire indicated a substantial benefit when rating effectiveness, itching and appearance.
This study indicates that Relieva® is useful in adult patients with atopic dermatitis.
Apollo Pharmaceuticals continuous research in dermatology offers another option for the treatment of adult patients with Atopic Dermatitis (eczema).
About Eczema
"Eczema is a cruel disease that is often mistaken as just a rash but can have a profound impact on patients' quality-of-life and emotional well-being, particularly in children. It not only afflicts the patients, their friends and family are also affected by the emotional impact"`.
Eczema affects approximately 17% of the U.S. population and is often a distressing condition characterized by itchy, scaly, dry, inflamed skin. It is estimated that 90% of eczema patients experience symptoms before the age of 5. Many patients, especially children, experience a significant emotional impact, feeling 'different'and/or left out. Feelings of social isolation and lack of sleep due to night-time itching demonstrate of how eczema impacts a patient's daily live.
A global study comprised of interviews with 2,002 patients from eight countries over the age of 13, and caregivers of children between the ages of 2-13, with moderate to severe eczema showed that on average, 86% of patients avoid at least one type of everyday activity during a flare-up and 74% of patients and caregivers state that their physicians have never discussed the emotional impact that eczema has had on their lives. (www.nationaleczema.org)
About Medicalread Staff